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Edited by Veli-Pekka LehtoAbstract Steﬁn B (cystatin B) is an inhibitor of lysosomal cys-
teine cathepsins and does not inhibit cathepsin D, E (aspartic) or
cathepsin G (serine) proteinases. In this study, we have investi-
gated apoptosis triggered by camptothecin, staurosporin (STS),
and anti-CD95 monoclonal antibody in the thymocytes from
the steﬁn B-deﬁcient mice and wild-type mice. We have observed
increased sensibility to STS-induced apoptosis in the thymocytes
of steﬁn B-deﬁcient mice. Pretreatment of cells with pan-caspase
inhibitor z-Val-Ala-Asp(OMe)-ﬂuoromethylketone completely
inhibited phosphatidylserine externalization and caspase activa-
tion, while treatment with inhibitor of calpains- and papain-like
cathepsins (2S,3S)-trans-epoxysuccinyl-leucylamido-3-methyl-
butane ethyl ester did not prevent caspase activation nor
phosphatidylserine exposure. We conclude that sensitization to
apoptosis induced by STS in thymocytes of steﬁn B-deﬁcient
and wild-type mice is not dependent on cathepsin inhibition by
steﬁn B.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Programmed cell death (apoptosis) is essential to many bio-
logical processes in multicellular organisms, including embry-
onic development, immune responses, tissue homeostasis and
normal cell turnover [1]. Proteolytic activity plays an impor-
tant role in apoptosis and caspases appear to be essential for
the execution of apoptotic process [2]. However, other cysteine
proteases distinct from caspases have been suggested to be in-
volved in apoptosis [3,4]. Cathepsins have traditionally been
viewed as lysosomal mediators of protein turnover, however,
recent ﬁndings have extended their role in other physiological
processes including apoptosis [5,6]. The cysteine cathepsins BAbbreviations: Ac-DEVD-AMC, acetyl-Asp-Glu-Val-Asp-AMC;
AFC, 7-amino-4-triﬂuoromethyl coumarin; AMC, 7-amino-4-methyl
coumarin; CPT, camptothecin; DMSO, dimethylsulfoxide; PS, phos-
phatidylserine; STS, staurosporin; z-VAD-fmk, benzyloxycarbonyl-
Val-Ala-Asp-fmk; fmk, ﬂuoromethyl ketone; E-64d, (2S,3S)-trans-
epoxysuccinyl-leucylamido-3-methyl-butane ethyl ester
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pase-dependent and caspase-independent apoptosis induced
by several stimuli, including death receptors of the TNFR fam-
ily, B cell receptors, camptothecin (CPT), and bile salt oxidants
[7–12].
Steﬁn B (also called cystatin B) belongs to cystatin family
of endogenous cysteine protease inhibitors [13]. Mutations
in the gene encoding steﬁn B are responsible for the primary
defect in Unverricht–Lundborg disease (EPM1) [14–16]. Ste-
ﬁn B-deﬁcient mice, produced by targeted disruption of the
mouse steﬁn B gene, display a phenotype similar to the hu-
man disease with progressive ataxia and myoclonic seizures
[17]. The mice exhibit apoptosis of cerebellar granule cells
and have increased expression of apoptosis and glial activa-
tion genes [18]. Although, steﬁn B has long been known to
inhibit in vitro papain-like cathepsins by tight and reversible
binding, the physiological function of steﬁn B in the molecu-
lar pathogenesis of the disease remains unknown. In vitro ste-
ﬁn B binds tightly to cathepsins H, L, and S, and less tightly
to cathepsin B [13]. Houseweart et al. [19] showed that the
removal of cathepsin B from cystatin B-deﬁcient mice greatly
reduced the neuronal apoptosis, but did not rescue the ataxia
and seizure phenotypes and concluded that besides cathepsin
B there are other factors involved. Recent studies show that
cathepsins cleave the pro-apoptotic Bcl-2 family member
Bid, thereby activating it and allowing it to induce the mito-
chondrial release of cytochrome c and subsequent apoptosis
[20,21]. At least in steﬁn B-deﬁcient mice Bid signaling is
not essential for apoptosis [22]. In contrast to T cell lines,
PS exposure in primary T cells undergoing apoptosis by stau-
rosporin (STS), etoposide, or interleukin 2 withdrawal is cas-
pase-independent, while anti-CD95 triggered apoptosis is
caspase-dependent [23].
We wanted to investigate if cell death and PS exposure in
thymocytes of steﬁn B-deﬁcient mice is cathepsin- or cas-
pase-dependent. Therefore, steﬁn B-deﬁcient thymocytes and
thymocytes from wild-type mice were treated with CPT,
STS, and anti-CD95 antibody. Thymocytes from steﬁn B-
deﬁcient mice exerted a markedly increased response, when
they were exposed to STS, compared to thymocytes from
wild-type mice. Preincubation of cells with (2S,3S)-trans-
epoxysuccinyl-leucylamido-3-methyl-butane ethyl ester (E-
64d) did not prevent apoptosis, while caspase inhibitor
z-VAD-fmk completely prevented apoptosis in all cases
tested. In thymocytes isolated from wild-type mice and of ste-
ﬁn B-deﬁcient mice, apoptosis is cathepsin-independent and
caspase-dependent.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Horseradish peroxidase-conjugated goat-anti-rabbit IgG and goat-
anti-mouseantibodies, fetal calf serum(FCS),wereobtained fromSigma
(USA). The caspase substrate acetyl-Asp-Glu-Val-Asp-7-amino-4-tri-
ﬂuorometyl coumarin (Ac-DEVD-AFC) was purchased from Bachem
(BachemAG, Switzerland). All other chemicalswere of analytical grade.2.2. Mice
Steﬁn B (cystatin B)-deﬁcient mice mice were created as described
previously [17]. Steﬁn B-deﬁcient mice bred on a C57BL/6 background
were kindly provided by Dr. R.M. Myers, Stanford University (USA)
and bred in our local colony, where background was changed on Balb/
c. All mice were genotyped by PCR as previously described [17].2.3. Cell preparations and cell culture
Freshly prepared thymocytes from thymus glands of 6- to 7-week-
old mice were plated in DMEM, 10% FCS, and 2 mM L-glutamine
in 24-well culture plates at 5 · 106 cells/well. The cell-permeable inhib-
itors E-64d (Peptide Institute, Osaka, Japan), or z-VAD-fmk (Bachem
AG, Switzerland) were added in adequate concentrations in dimethyl-
sulfoxide (DMSO) 1 h prior to induction of apoptosis. The corre-
sponding volume of DMSO was added to the control cultures. To
induce apoptosis, cells were treated with CPT (Sigma, USA) (1 lM),
STS (Sigma) (1 lM) or with anti-CD95 mAb Jo-2 (Pharmingen,
USA) (500 ng/ml) for 4, 8, 12 and 18 h.
Human Jurkat T cell line was purchased from American Type Cul-
ture Collection (Manassas, VA, USA). Cells were grown in RPMI
1640 medium supplemented with 10% FCS, 2 mM glutamine, and
1000 U/ml of penicillin–streptomycin. Cells were treated with CPT
(1 lM), STS (1 lM) or with anti-CD95 mAb CH11 (Pharmingen)
(1 lg/ml).
Preparation of cell lysates and immunoprecipitates. For protein anal-
ysis, cells were lysed with radioimmunoprecipitation assay (RIPA) buf-
fer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% deoxycholate, 1%
Triton X-100, and 5 mM EDTA). Cell lysates were clariﬁed by centri-
fugation at 12000 rpm for 10 min at 4 C. Protein concentration of the
supernatants were determined by Bradford assay, and equivalent
amounts of protein from cell lysates were used for immunoprecipita-
tion or analyzed directly by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) followed by Western blotting. For immunoprecipita-
tions RACK-1 mAb (Pharmingen) was added to lysates and allowed
to rock at 4 C for 2 h. Then, 5 lg of anti-mouse IgM Ab and 50 ll
of protein A–Sepharose beads (Amersham Pharmacia Biotech, Swe-
den) were added to the lysates, which were allowed to rock for another
2 h at 4 C. Immunoprecipitates were washed twice in fresh cold RIPA
buﬀer. Washed immunoprecipitates and total cell lysates were dena-
tured by boiling after the addition of one-sixth of the volume of 6·
reducing SDS–PAGE sample buﬀer (360 mM Tris, pH 6.6, 12%
SDS, 600 mM DTT, 60% glycerol, and 0.6% bromophenol blue) and
analyzed by immunoblotting.
Western blot. Proteins were separated on 15% SDS–PAGE and elec-
trophoretically transferred to nitrocellulose ﬁlters in 192 mM glycine,
25 mM Tris, and 20% (v/v) methanol. The membrane was blocked
by incubating in phosphate buﬀered saline pH 7.2 containing 0.5%
(v/v) Tween-20 (PBST) containing 5% (wt/vol) nonfat dry milk and
sequentially incubated with primary Ab: rabbit anti-human caspase-3
Ab or mouse anti-human caspase-7 mAb F5/1 (Gregorc, U., Dober-
sˇek, A., Salvesen, G., Turk V., Turk, B., Kopitar-Jerala, N. accepted
to Immunology Lett.) and with anti-b-actin antibody (Sigma–Adrich,
USA) in PBST for 1–2 h with shaking. Anti-RACK-1 immunoprecip-
itates were developed with anti-cystatin B (steﬁn B) Ab (Biogenesis,
Poole, UK). The ﬁlters were incubated with horseradish peroxidase-
conjugated secondary anti-mouse or anti-rabbit Ab (depending on
the primary Ab). Membranes were then washed with PBST and devel-
oped by the enhanced chemiluminescence method according to the
manufacturers instructions (Amersham Pharmacia Biotech).Fig. 1. Dose-dependent eﬀect of STS on DEVD-ase activity.
Thymocytes from Balb/c mice were treated with increasing concentra-
tions of STS for 8 h. DEVD–AFC cleavage activity was determined as
described in Section 2.2.4. Measurement of DEVD-ase activity
For measurement of caspase activities, treated cells were washed in
PBS and pellets were lysed for 15 min at 4 C in caspase lysis buﬀer
(100 mM HEPES, 200 mM NaCl, 0.2% (w/v) CHAPS (3-[(3-cholami-dopropyl) dimethylammonio]-1-propanesulfonate), 20% (w/v) sucrose,
2 mM EDTA, and 20 mM DTT, pH 7.0). After 15 min centrifugation
at 12,000 · g and 4 C, supernatant were collected and assayed for pro-
tein concentration by Bradford method (Bio-Rad Laboratories, USA).
Caspase-3 and -7 activities were estimated on 100 lg of proteins by
adding caspase buﬀer to the ﬁnal volume of 90 ll into the 96-well plate.
Following 10 min incubation at 37 C, Ac-DEVD-AFC (Ac-Asp-Glu-
Val-Asp-7-amido-4-methyl coumarin) was added to a ﬁnal concentra-
tion of 100 lM and DEVD-ase activity was measured continuously in
an LS50B ﬂuorimeter with plate reader attachment (Perkin–Elmer,
USA) at excitation and emission wavelengths of 400 and 505 nm,
respectively.
2.5. Flow cytometry
Phosphatidylserine exposure was measured by labelling thymocytes
with annexin V-PE and 7-amino-actinomycin D (7-AAD) (Becton
Dickinson, USA) according to the manufacturers instructions. Cells
were then subjected to FACS analysis using a FACScalibur ﬂow
cytometer (Becton Dickinson) and CellQuest software.3. Results
3.1. Steﬁn B-deﬁcient thymocytes are more sensitive to protein
kinase inhibitor staurosporin-induced apoptosis
As a ﬁrst approach to assess the role of steﬁn B in extrinsic
or intrinsic apoptotic signalling pathway the kinetics of cas-
pase activation and PS externalization were compared in thy-
mocytes from wild-type mice with thymocytes from steﬁn
B-deﬁcient mice treated with anti-CD95 mAb, STS, and
CPT. Caspase activation was ﬁrst studied by ﬂuorimetric assay
using the caspase-3 and -7 speciﬁc substrate Ac-DEVD-afc.
The dose-dependent eﬀect of STS on DEVD-ase activity is
shown in Fig. 1. In thymocytes of steﬁn B-deﬁcient mice as
well as wild-type thymocytes the time course of cell death in-
duced by anti-CD95 mAb was more rapid (4–8 h) than with
CPT or STS (Fig. 2A–C). Examination of the time-dependent
activation of DEVD-ase induced by STS revealed that DEVD-
ase activity began to increase approximately 4 h after STS
treatment and reached maximum after 8–12 h. Addition of
STS caused a signiﬁcantly faster caspase activation in the thy-
mocytes of steﬁn B-deﬁcient mice in comparison to wild-type
mice (Fig. 2B). In the case of anti-CD95 mAb antibody and
CPT the diﬀerences between DEVD-ase activities in steﬁn
Fig. 3. PS surface exposure in thymocytes isolated from wild-type
(WT) and steﬁn B-deﬁcient (KO) mice undergoing apoptosis by
diﬀerent stimuli. Thymocytes were treated with CPT (1 lM), STS
(1 lM), or anti-CD95 mAb (0.5 lg/ml) for 6 h. At this time cells were
stained with annexin V-FITC and 7AAD. The percentages of annexin
V/7AAD, annexin V+/7AAD, and annexin V+/7AAD+ are indi-
cated on each dot plot. Results are from a typical experiment of three
performed that showed similar percentages.
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Fig. 2. Kinetic analysis of caspase activation associated with apoptosis
triggered by diﬀerent stimuli in thymocytes from wild-type mice and
steﬁn B-deﬁcient mice. Thymocytes from wild-type mice (h) and steﬁn
B-deﬁcient mice (n) were treated with (A) anti-CD95 mAb (0.5 lg/ml);
(B) STS (1 lM); (C) or CPT (1 lM). At the indicated time, DEVD–
AFC cleavage activity was determined as described in Section 2. The
results are means ± S.D. of at least three independent experiments
performed in duplicate.
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as in the case of STS (Fig. 2A and C).
The kinetics of PS externalization was observed by cytoﬂu-
orometric analysis using annexin V-7AAD, respectively. Upon
induction of apoptosis with STS, thymocytes from steﬁn B-
deﬁcient mice showed increased PS exposure in comparison
to thymoctes from wild-type mice (Fig. 3).
Together these results show a concomitant caspase activa-
tion and PS exposure after STS, CPT, anti-CD95 mAb-in-
duced apoptosis. Such kinetics suggest that in thymocytes PS
exposure is dependent on caspase activation after STS, CPT,
or anti-CD95 mAb-induced apoptosis. Extracts of apoptotic
cells were tested with Western blots for the caspase-3 and -7
processing. In the extracts from the thymocytes of steﬁn B-
deﬁcient and wild-type mice both caspase-3 and -7 were pres-
ent in proteolytically processed activated form (Fig. 4).
Processing of caspase-3 in untreated thymocytes is due to the
spontaneous apoptosis in thymocytes in primary culture,
after 8 h.3.2. Steﬁn B and RACK-1 do not co immunoprecipitate in the
thymocytes of Balb/c mice
We tested if the increased sesnsitivity of steﬁn B-deﬁcient
thymocytes is to STS-induced apoptosis is due to interactions
of steﬁn B with RACK-1, since co-immunoprecipitation of the
two proteins was described in rat cerebellar cell extracts [35].
With speciﬁc antibodies we were able to detect RACK-1 as
well as steﬁn B in thymocyte lysates of Balb/c mice using Wes-
tern blot, but we could not detect the interaction of the two
proteins with co-immunoprecipitation (data not shown).
3.3. Cysteine proteinase inhibitor E-64d does not prevent
apoptosis in steﬁn B-deﬁcient nor in wild-type thymocytes
To determine whether cysteine endopeptidases (lysosomal
papain-like cathepsins or calpains) have an active role within
apoptotic pathways in thymocytes we used the previously
characterized cell-permeable inhibitor E-64d. Our previous re-
sults on Jurkat T cells show that preincubation with E-64d
even in concentrations as low as 5 lM was suﬃcient to com-
pletely block any cathepsin activity [24]. Here we present evi-
dence that inhibition of cathepsin activity did not protect
Fig. 5. Eﬀects of cathepsin inhibitor E-64d on PS exposure in
thymocytes isolated from from wild-type (WT) and steﬁn B-deﬁcient
(KO) mice undergoing apoptosis by diﬀerent stimuli. Thymocytes were
incubated in the presence of E-64d (25 lM) for 1 h before treatment
with CPT (1 lM), STS (1 lM), or anti-CD95 mAb (0.5 lg/ml) for 6 h.
At this time cells were stained with annexin V-PE and 7AAD. The
percentages of annexin V/7AAD, annexin V+/7AAD, and annexin
V+/7AAD+ are indicated on each dot plot. Results are from a typical
experiment of three performed that showed similar percentages.
Fig. 4. Caspase-7 and -3 activation during CD95-, STS-, and CPT-
induced apoptosis in thymocytes. Cells from wild-type (lines 1, 3, 5, 7)
and steﬁn B-deﬁcient mice (2,4,6,8) were left untreated (1,2) treated
with STS (3, 4), CPT (5, 6), or anti-CD95 mAb (7, 8) for 8 h. After
washing with PBS, cells were lysed as described in Section 2. An equal
amount of proteins was loaded and separated on 15% SDS–PAGE,
followed by Western blotting with the anti-caspase-3 rabbit polyclonal
and sera anti-caspase-7 mAb F5/1. Membranes were stripped and
redeveloped with anti-b-actin Ab. Results are from a typical experi-
ment of two performed that showed similar results.
2152 N. Kopitar-Jerala et al. / FEBS Letters 579 (2005) 2149–2155primary culture of thymocytes from apoptosis. The eﬀect of E-
64d on the anti-CD95 mAb, STS and CPT-induced apoptosis
was examined by ﬂow cytometry. Pretreatment of thymocytes
with up to 25 lM of E-64d for 1 h prior to induction of apop-
tosis had no eﬀect on apoptosis determined by ﬂow cytometry
(Fig. 5). DEVD-ase activity after induction of apoptosis in
cells pretreated with E-64d and untreated cells was also com-
parable (data not shown).
3.4. Apoptosis is prevented by caspase inhibitor z-VAD-fmk in
both steﬁn B-deﬁcient and wild-type thymocytes
To assess the role of caspases in apoptosis induced in thymo-
cytes isolated from steﬁn B-deﬁcient and wild-type mice we
examined the eﬀect of the pan-caspase inhibitor Z-VAD-fmk
on PS exposure. z-VAD-fmk was found to inhibit also cathep-
sins in intact cells and in our experiments we used z-VAD-fmk
at concentrations that do not signiﬁcantly inhibit the cathep-
sins (25 lM) [24]. Cells preincubated with z-VAD-fmk inhibi-
tor for 1 h and treated with anti-CD95 mAb, STS, and CPT
were harvested for analysis of DEVD-ase activity and PS expo-
sure. Preincubation of thymocytes with 25 lM z-VAD-fmk
prevented not only DEVD-ase activity (data not shown) in
thymocytes isolated from steﬁn B-deﬁcient and wild-type mice,
but also PS exposure (Fig. 6), indicating that caspase activa-
tion is required for apoptosis progression in this model.
DEVD-ase activity and PS exposure was low also in negative
controls indicating that also spontaneous apoptosis in thymo-cytes in primary culture was prevented with z-VAD-fmk. Jur-
kat T cells were treated with the same apoptosis-inducing
stimuli, anti-CD95 mAb, STS, or CPT in the presence or the
absence of the pan-caspase inhibitor z-VAD-fmk or E-64d.
In Jurkat z-VAD-fmk inhibited PS exposure induced by anti-
CD95 mAb, as well as with CPT and STS while E-64d did
not inhibit caspase activation nor PS exposure induced by
anti-CD95 mAb (data not shown). Our results on induction
of apoptosis in Jurkat cell line are in accordance with previ-
ously published results [23].4. Discussion
In this study, we investigated the eﬀect of the lack of steﬁn B
in apoptotic pathways in thymocytes. In T cells and thymo-
cytes, caspases are not the only proteases that are able to in-
duce apoptosis, cathepsins and calpains could also
participate [25–27]. In thymocytes of steﬁn B deﬁcient mice
as well as in thymocytes isolated from wild-type mice the time
course of cell death induced by anti-CD95 mAb was more
Fig. 6. Eﬀects of caspase inhibitor z-VAD-fmk on PS exposure in
thymocytes from wild-type (WT) and steﬁn B-deﬁcient (KO) mice
undergoing apoptosis by diﬀerent stimuli. Thymocytes were incubated
in the presence of z-VAD-fmk (25 lM) for 1 h before treatment with
CPT (1 lM), STS (1 lM), or anti-CD95 mAb (0.5 lg/ml) for 6 h. At
this time cells were stained with annexin V-PE and 7AAD. The
percentages of annexin V/7AAD, annexin V+/7AAD, and annexin
V+/7AAD+ are indicated on each dot plot. Results are from a typical
experiment of three performed that showed similar percentages.
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comparable increase in caspase activity and cells surface PS
exposure in steﬁn B-deﬁcient and wild-type mice in apoptosis
induced by anti-CD95 mAb and concluded that steﬁn B is
not involved in extrinsic apoptotic pathway (Fig. 2A and
Fig. 3). We tested two reagents that act through intrinsic path-
way: in the apoptosis induced by CPT, topoisomerase inhibitor
which is also known to cause activation of NF-jB, there was
not a major diﬀerence between steﬁn B-deﬁcient and wild-type
thymocytes (Fig. 2C) NF-jB suppresses apoptosis through
induction of multiple target genes coding for inhibitors of
the extrinsic or intrinsic signalling pathways that regulate
apoptosis [28]. Recently, it has been shown that NF-jB pro-
tects cells from TNF-a-induced apoptosis by the up regulation
of serine protease inhibitor 2A (Spi2A), also an inhibitor of
cathepsin B [29]. The most pronounced diﬀerence between time
course of apoptosis in thymocytes of steﬁn B-deﬁcient and
wild-type mice we found with STS, a broad-speciﬁcity protein
kinase inhibitor. Although STS inhibits several protein ki-
nases, it shows the highest aﬃnity to the protein kinase C
(PKC) isoenzymes [30]. Despite the common use of STS as
an inducer of apoptosis, the mechanism by which STS initiatesapoptosis still not clear. It is apparent that STS induces apop-
tosis through the mitochondrial pathway [31]. Cells from mice
lacking both BAX and BAK are completely resistant to STS as
well as several other apoptotic stimuli that act through disrup-
tion of mitochondrial function [32]. STS induces mitochon-
drial outer membrane permeabilization, which is followed by
the release of cytochrome c and the downstream activation
of caspase-9 and -3 [31,33]. In STS induced apoptosis cas-
pase-3 to feeds back on permeabilized mitochondria and cleave
the 75-kDa subunit (NDUFS1) of respiratory complex I,
which leads to a disruption of electron transport, mitochon-
drial transmembrane potential (Dwm) and the production of
reactive oxygen species (ROS) [34]. The increased sensitivity
of steﬁn B-deﬁcient thymocytes towards STS-induced apopto-
sis could be at least partially due to the ROS.
Di Giaimo et al. [35] using yeast two hybrid system, identi-
ﬁed ﬁve proteins interacting with steﬁn B in rat cerebella, none
of which was cathepsin. We ﬁnd particularly interesting inter-
action of steﬁn B with protein kinase C receptor (RACK-1)
which was also conﬁrmed by co-immunoprecipitation of two
proteins in rat cerebellar cell extracts, and in immunoﬂuores-
cence analysis of diﬀerentiated cultured primary cerebellar
granule cells. RACK-1 was originally identiﬁed and cloned
from a rat brain cDNA expression library as a protein that
speciﬁcally bound activated PKCb.
We tested the possibility that steﬁn B interacts with RACK-1
and in this way interferes with PKC signalling in the cells. With
speciﬁc antibodies wewere able to detect RACK-1 as well as ste-
ﬁn B in thymocyte lysates of Balb/c mice usingWestern blot, but
we could not conﬁrm the interaction of the two proteins with co-
immunoprecipitation. The interaction of steﬁn B with RACK-1
is probably tissue speciﬁc, characteristic only to cerebellum.
Why steﬁn B-deﬁcient thymocytes are more sensitive to STS-in-
duced apoptosis is still not clear, but at least in murine thymo-
cytes, it is not due to steﬁn B–RACK-1 interactions.
Apoptotic pathways consist of a cascade of signalling proteins
before the ﬁnal decision ismade.We cannot exclude the possibil-
ity that the increased sensitivity of steﬁn B-deﬁcient thymocytes
towards STS-induced apoptosis is due to STS inhibition of PKC
and lack of phosphorylation of signalling proteins.
Two independent studies identiﬁed cathepsin B as a key
player in microglial neuronal cell death [36,37]. In WEHI-S ﬁ-
bro sarcoma cells, TNF-a induced an increase in cytosolic
cathepsin B activity followed by death with apoptotic features.
Apoptosis was enhanced by low concentrations of pan-caspase
inhibitors z-VAD-fmk. Contrary to caspase inhibitors, a panel
of pharmacological cathepsin B inhibitors, the endogenous
cathepsin inhibitor steﬁn A (cystatin A) as well as antisense-
mediated depletion of cathepsin B rescued WEHI-S cells from
apoptosis [7]. Since steﬁn B is inhibitor of cysteine proteinases
and does not inhibit cathepsin D, E (aspartic) or cathepsin G
(serine) proteinases we examined the eﬀect of E-64d on apop-
tosis in steﬁn B deﬁcient thymocytes. In our experiments inhi-
bition of cathepsin activity with E-64d did not rescue
thymocytes isolated from steﬁn B-deﬁcient mice nor wild-type
mice from apoptosis with any apoptotic inducers tested. Cal-
pains, calcium-dependent cysteine proteases, which are also
inhibited by E-64d, are required for polymorphonuclear neu-
trophil apoptosis, as well as for glucocorticoid-induced apop-
tosis thymocytes [4,38]. But the lack of inhibition of
apoptosis with E-64d, suggested that in our test system cal-
pains were not involved. It can be therefore suggested that
2154 N. Kopitar-Jerala et al. / FEBS Letters 579 (2005) 2149–2155the sensitization of thymocytes to STS-induced apoptosis is
not related to lack of inhibition of cathepsins by steﬁn B.
The inhibition of caspase activity with general caspase inhib-
itor z-VAD-fmk completely prevented apoptosis in thymocytes
isolated from steﬁn B-deﬁcient mice as well as wild-type mice
(Fig. 6). In our test system of apoptosis induced in murine thy-
mocytes PS exposure is connected to caspase activation, while
in primary T cells, PS exposure was not aﬀected by caspase
inhibitors [23].
As a conclusion, we can say that in thymocytes isolated from
wild-type mice and steﬁn B-deﬁcient mice, apoptosis is cathep-
sin-independent and caspase-dependent, while the steﬁn B deﬁ-
ciency aﬀects predominantly apoptotic process which is
triggered by STS by a currently unknown mechanism.
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